239 related articles for article (PubMed ID: 29276353)
1. A Cross-Sectional Study on the Characteristics of Tardive Dyskinesia in Patients with Chronic Schizophrenia.
Huang Y; Pan L; Teng F; Wang G; Li C; Jin L
Shanghai Arch Psychiatry; 2017 Oct; 29(5):295-303. PubMed ID: 29276353
[TBL] [Abstract][Full Text] [Related]
2. Tardive dyskinesia is associated with greater cognitive impairment in schizophrenia.
Wu JQ; Chen DC; Xiu MH; Tan YL; Yang FD; Kosten TR; Zhang XY
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():71-7. PubMed ID: 23827756
[TBL] [Abstract][Full Text] [Related]
3. Sex difference in association between tardive dyskinesia and cognitive deficits in patients with chronic schizophrenia.
Zhang W; Wang D; Zhou H; Chen D; Xiu M; Cui L; Zhang X
Schizophr Res; 2023 May; 255():140-147. PubMed ID: 36989671
[TBL] [Abstract][Full Text] [Related]
4. [Tardive dyskinesia induced by classical antipsychotic drugs: a Tunisian sample of schizophrenics].
Sejil I; Oumaya A; Bouguerra C; Mehdi F; Bellaaj R; Gallali S
Encephale; 2013 May; 39 Suppl 1():S36-41. PubMed ID: 23219594
[TBL] [Abstract][Full Text] [Related]
5. Prevalence, clinical correlates and risk factors associated with Tardive Dyskinesia in Chinese patients with schizophrenia.
Uludag K; Wang DM; Goodman C; Chen DC; Wang L; Zhang X
Asian J Psychiatr; 2021 Dec; 66():102877. PubMed ID: 34638091
[TBL] [Abstract][Full Text] [Related]
6. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.
Caroff SN; Davis VG; Miller DD; Davis SM; Rosenheck RA; McEvoy JP; Campbell EC; Saltz BL; Riggio S; Chakos MH; Swartz MS; Keefe RS; Stroup TS; Lieberman JA;
J Clin Psychiatry; 2011 Mar; 72(3):295-303. PubMed ID: 20816031
[TBL] [Abstract][Full Text] [Related]
7. Neuroleptic withdrawal in treatment-resistant patients with schizophrenia: tardive dyskinesia is not associated with supersensitive psychosis.
Apud JA; Egan MF; Wyatt RJ
Schizophr Res; 2003 Sep; 63(1-2):151-60. PubMed ID: 12892869
[TBL] [Abstract][Full Text] [Related]
8. Smoking and tardive dyskinesia in male patients with chronic schizophrenia.
Zhang XY; Yu YQ; Sun S; Zhang X; Li W; Xiu MH; Chen DC; Yang FD; Zhu F; Kosten TA; Kosten TR
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1765-9. PubMed ID: 21723906
[TBL] [Abstract][Full Text] [Related]
9. White matter abnormalities in schizophrenia patients with tardive dyskinesia: a diffusion tensor image study.
Bai YM; Chou KH; Lin CP; Chen IY; Li CT; Yang KC; Chou YH; Su TP
Schizophr Res; 2009 Apr; 109(1-3):167-81. PubMed ID: 19261444
[TBL] [Abstract][Full Text] [Related]
10. Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia.
Adelufosi AO; Abayomi O; Ojo TM
Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD010501. PubMed ID: 25866243
[TBL] [Abstract][Full Text] [Related]
11. Tardive dyskinesia in Chinese patients with schizophrenia: Prevalence, clinical correlates and relationship with cognitive impairment.
Liang Q; Wang D; Zhou H; Chen D; Xiu M; Cui L; Zhang X
J Psychiatr Res; 2022 Jul; 151():181-187. PubMed ID: 35489178
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342
[TBL] [Abstract][Full Text] [Related]
13. Gray matter abnormalities in schizophrenia patients with tardive dyskinesia: a magnetic resonance imaging voxel-based morphometry study.
Li CT; Chou KH; Su TP; Huang CC; Chen MH; Bai YM; Lin CP
PLoS One; 2013; 8(8):e71034. PubMed ID: 23967150
[TBL] [Abstract][Full Text] [Related]
14. Decreased Gray Matter Volume of Cuneus and Lingual Gyrus in Schizophrenia Patients with Tardive Dyskinesia is Associated with Abnormal Involuntary Movement.
Yu T; Li Y; Fan F; Cao H; Luo X; Tan S; Yang F; Zhang X; Shugart YY; Hong LE; Li CR; Tan Y
Sci Rep; 2018 Aug; 8(1):12884. PubMed ID: 30150749
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340
[TBL] [Abstract][Full Text] [Related]
16. Impact of drug-induced Parkinsonism and tardive dyskinesia on health-related quality of life in schizophrenia.
Rekhi G; Tay J; Lee J
J Psychopharmacol; 2022 Feb; 36(2):183-190. PubMed ID: 34979813
[TBL] [Abstract][Full Text] [Related]
17. Correlates of the Abnormal Involuntary Movement Scale in Veterans With Tardive Dyskinesia.
Caroff SN; Leong SH; Roberts CB; Berkowitz RM; Campbell EC
J Clin Psychopharmacol; 2020; 40(4):373-380. PubMed ID: 32639290
[TBL] [Abstract][Full Text] [Related]
18. Reduced serum TNF alpha level in chronic schizophrenia patients with or without tardive dyskinesia.
Tian L; Tan Y; Chen D; Lv M; Tan S; Soares JC; Zhang XY
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Oct; 54():259-64. PubMed ID: 24995685
[TBL] [Abstract][Full Text] [Related]
19. BDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: a meta-analysis.
Miura I; Zhang JP; Nitta M; Lencz T; Kane JM; Malhotra AK; Yabe H; Correll CU
Schizophr Res; 2014 Feb; 152(2-3):365-72. PubMed ID: 24411528
[TBL] [Abstract][Full Text] [Related]
20. The Tardive Dyskinesia Impact Scale (TDIS), a novel patient-reported outcome measure in tardive dyskinesia: development and psychometric validation.
Farber RH; Stull DE; Witherspoon B; Evans CJ; Yonan C; Bron M; Dhanda R; Jen E; Brien CO'
J Patient Rep Outcomes; 2024 Jan; 8(1):2. PubMed ID: 38175450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
